Wilmer Cutler Pickering Hale and Dorr represented Beam Therapeutics Inc., and Davis Polk & Wardwell advised the underwriters in the offering. Beam Therapeutics Inc. (Nasdaq: BEAM)...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Mediar Therapeutics in the transaction. Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Agios Pharmaceuticals, Inc. in the deal. Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation...
You must be a Standard 1 Year member to access this content.
Ropes & Gray and Wilmer Cutler Pickering Hale and Dorr represented Xilio Therapeutics, Inc. in the deal. Xilio Therapeutics, Inc.(Nasdaq: XLO), announced it has entered into...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Infinity Pharmaceuticals on the deal, while Morgan Lewis represented MEI Pharma Inc. Infinity Pharmaceuticals and MEI Pharma announced that...
You must be a Standard 1 Year member to access this content.
WilmerHale represented Volastra Therapeutics on the deal. Volastra Therapeutics, a clinical stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), closed its $60 million Series...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented LG Chem in the transaction, while WilmerHale LLP represented AVEO. LG Chem, Ltd. (KOSPI: 051910) entered into a definitive agreement to acquire...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr LLP advised Volastra Therapeutics on the deal. Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment...
You must be a Standard 1 Year member to access this content.
